• darkblurbgdarkblurbg
  • darkblurbg
  • darkblurbg
  • darkblurbg
CBM2
Center of BioModular Multi-Scale Systems for Precision Medicine
A National Biotechnology Resource Center
part
Picture of replicated part

CBM2 Vision

CBM2 is a multi-institutional Center (The University of Kansas, Louisiana State University, and The University of North Carolina-Chapel Hill), and is supported by the Biotechnology Resource Center mechanism from the National Institutes of Health (National Institute of Biomedical Imaging and Bioengineering; NIBIB).

CBM2 vision is to design, manufacture, and deliver new tools to the biomedical community that utilize liquid biopsies for disease detection and management — Precision Medicine. Our vision is being realized through the delivery of innovative and fully automated mixed-scale systems programmed for different disease states.

Core Technologies

  • CBM2 has built a strong infrastructure to support our Core Technologies and your ideas.
  • CBM2 has expertise across many different disciplines (i.e., engineering, medicine, basic sciences).
  • CBM2 partnering institutions provide collaboration and service opportunities for a wide range of researchers from academic, governmental, and industrial settings.
  • Designing,and fabricating plastic-based microfluidic and nanofluidic devices for a broad range of biomedical areas.
  • Developing innovative tools for the analysis of liquid biopsy markers to enableprecision medicine.

Plastic Microfluidics and Nanofluidics

plastic microfluidics and nanofluidics
  • New tools are necessary for the analysis of liquid biopsy markers to allow for better patient outcomes.
  • In vitro diagnostics is a growing area in the medical field, especially with the advent of precision medicine.
  • New technologies evolving from CBM2 seek to deliver point of care devices for the in vitro diagnostics. Key advantages of our Core Technologies are:
       
    • Thermoplastic devices: manufacturing in a high-scale production mode at low cost to translate devices into the in vitro diagnostic area.
    • Integrated systems that can fully automate the sample processing pipeline, especially when dealing with liquid biopsy samples.
    • Robust methods to assemble cover plates to devices with high process yield rates for both microfluidic and nanofluidic devices.
    • A wealth of experiences in modifying the chemical properties of plastic devices to accommodate applications in biology, medicine, and other areas.

Employment Opportunities

Administrative Assistant Chemistry
The department of Chemistry at the University of Kansas is looking for an Administrative Assistant. This person will report to the Center Director and will assist in the day-to-day activities of the Center in terms of operational logistics and help to coordinate visits of NIH staff, the External Advisory Board and Collaborating Scientists. This is a full-time position.

CBM2 Develops Innovative Test for COVID-19

Collaborative & Service Projects

The Center seeks to disseminate its Core Technologies into the research and clinical domains. The Center can accomplish this through a variety of mechanisms and is enthusiastic to discuss this with you. In particular, we can support efforts in such areas as liquid biopsy analyses, and designing and building microfluidic and nanofluidic devices for a variety of application areas.

Read More

Visiting Scholar Program

jason_emory
Prof. Jason Emory of Pfeiffer University. Prof. Emory was a visiting scholar at our Center in the summer of 2019 and worked at the University of Kansas – Lawrence.

CBM2 invites researchers (national and international) at all levels and interested in learning more about our core competencies, which include plastic-based microfluidics/nanofluidics and liquid biopsies, to visit our laboratories for extended periods-of-time as part of our visiting scholar program. Due to the geographical distribution of our Center, visiting scholars can select to visit UNC-Chapel Hill, Louisiana State University, or the University of Kansas (the Medical Center or the Lawrence campus).

During your stay, you can directly participate in experiments that match your learning needs. The length of stay is entirely up to the visiting scholar; we have had visiting scholars that have stayed over the summer months or even an entire year. If you are interested, please click on the “Read More” tab below to learn more about this program.

Precision Medicine

Precision Medicine

The "Precision Medicine" initiative was announced by President Obama in his January 20th, 2016 State of the Union address. President Obama said he wanted the United States to "lead a new era of medicine, one that delivers the right treatment at the right time."

Rather than the current one-size-fits-all approach, drugs will be tailored to individuals allowing doctors to target the precise form a disease takes in any individual and avoid administering drugs that may be ineffective or even harmful.

CBM2 is making timely and important discoveries for the Precision Medicine initiative by developing state-of-the-art tools that can transition quickly into the clinic to provide diagnostic and prognostic information currently inaccessible to the patient due to limitations in current testing platforms.